Background Predictive factors for the efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors for decreasing glycosylated hemoglobin (HbA1c) remain unclear in individuals with type 2 diabetes mellitus. in another window CI, self-confidence period; HbA1c, glycosylated hemoglobin. Protection of DPP-4 inhibitor treatment On the 12-month DPP-4 inhibitor treatment period, no individuals experienced severe unwanted effects, such as for… Continue reading Background Predictive factors for the efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors